Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Statins are a class of drugs given to lower cholesterol. Although statins are considered to be generally safe, some studies show that about 10% of people on statins develop muscle-related symptoms, from fatigue (tiredness), weakness, cramping, pain and sometimes a lifethreatening muscle breakdown condition known as rhabdomyolysis. In some, these symptoms may greatly affect their daily activities. One consideration why symptoms develop in only some patients is that they may have an underlying problem in the way their muscles use fats to produce energy. In these patients, the muscles are not able to fully utilize fats and so they become tired more easily. Fat within the muscle can also affect how your body uses a hormone called insulin, which affects your blood sugar levels. The investigators are specifically interested in previous statin users and determine if the muscle symptoms are related to changes in energy and sugar use. We propose to enroll patients who have developed muscle side effects on previous statin treatment and have since discontinued statin treatment.

Our aim is to compare the metabolic parameters in these patients to age and gender-matched normal individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopathy (Statin Associated)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Controls

No interventions assigned to this group

Statin associated myopathy

subjects with statin associated myopathy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

SAM Group

1. Males and females 40-65 yrs old; females must be post-menopause (\>12 months since last menstrual period)
2. Developed statin-associated myopathy, defined as:

* Documented elevated levels of CPK \> 3x upper limit of normal with muscle pain, weakness, cramping during statin treatment, or
* Diagnosed with rhabdomyolysis, or
* Developed muscle pain, weakness, cramping during statin treatment that resulted in statin discontinuation by the subject's MD
* Developed recurrence of muscle symptoms after resumption of statin treatment, or A score of at least 5/17 on the INQoL on screening on any of the aspects of muscle symptoms (weakness, pain, locking or tiredness) based on subject's recall at the height of the muscle symptoms
3. Able to ambulate independently (in order to perform exercise tests)
4. Muscle symptoms started/ occurred within one year of starting statin treatment or within one year of changing statin brand or dose adjustment
5. Discontinued statins at least 2 months from study inclusion date
6. 20% probability of having a cardiovascular (CV) event in the next 10 years calculated using an online CV risk calculator AND with a low or a moderate American College of Sports Medicine (ACSM) risk stratification for a cardiovascular event during a treadmill test

Normal Control Group

1. Age and gender-matched individuals who are not on statins but would otherwise be candidates for statin treatment based on ATP III guidelines and have not experienced severe muscle pain, weakness or cramping at rest or during exercise
2. Have not been diagnosed with a myopathy
3. Have no family history of a myopathy or age and gender-matched individuals who have previously been on statins and did not develop muscle side effects, and have been off statins (for other than medical reasons) for at least 2 months from study inclusion
4. 20% probability of having a cardiovascular (CV) event in the next 10 years calculated using an online CV risk calculator AND with a low or a moderate American College of Sports Medicine (ACSM) risk stratification for a cardiovascular event during a treadmill test

Exclusion Criteria

Applies to both groups of subjects

1. Current treatment with other lipid-lowering agents, or intake of red yeast rice
2. Impaired liver or kidney function ( ALT or AST 3x upper limit of normal, creatinine 3x upper limit of normal)
3. Untreated hypo or hyperthyroidism
4. Documented history of muscle disorder or myopathy other than statin-associated myopathy or previous history of elevated CPK prior to statin exposure
5. Anemia (Hb\< 110 g/dL)
6. Cancer
7. Known diabetes or fasting blood glucose \>126 mg/dL
8. HIV-1 infection
9. Uncontrolled blood pressure 130/80 on two anti-hypertensive drugs
10. Currently taking beta blockers
11. Known coronary artery disease or peripheral vascular disease
12. Chronic illnesses such as lupus, rheumatoid arthritis, psoriasis
13. Long term oral, nasal, or inhaler steroid use \> 6 months
14. On Hormone Therapy except for thyroid replacement
15. Alcohol consumption 40 g/day (3 glasses/day wine or beers or binge drinking 4 glasses/night)
16. Surgery in the past 6 months except for minor excision/incision procedures, 12-L electrocardiogram demonstrating old/new myocardial infarction/ ischemia or other findings that, at the investigators' discretion, may put the subject at high risk
17. Cognitive impairment that prevents comprehension of questionnaires
18. Inability to read English (questionnaire language)
19. Body mass index \> 30 kg/m2
20. Physical disability or previous injury that prevents safe exercise testing
21. Not eligible for MRS (attachment)

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Rockefeller University

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAM-0672

Identifier Type: -

Identifier Source: org_study_id